Chimeric Antigen Receptor T Cell Therapy (CAR-T): Genetically programmed immune cell binds to and destroys cancer cell / Therapy is now available for the majority of indications
2. February 2022 • Diagnostics
2. February 2022 • Diagnostics
The University of Leipzig is contributing its expertise in individualized cancer therapy to three new research projects. The Saxon Ministry of Science will fund the projects from the local site and one from Dresden with a total of 2.3 million euros over the next three years. Individualized cancer therapy is the focus of research.
Personalized medicine means tailoring the best possible treatment for each patient. The Saxon Ministry of Science funds four research projects for individualized cancer therapy with around 2.3 million euros. The projects will start in 2022 and run for three years.
The University of Leipzig is contributing its expertise to three of the four projects: The Institute of Computer Science is supporting a project on lung cancer research (Prof. Dr. Erhard Rahm). In addition, the Department of Nuclear Medicine at the University Hospital is participating in a project to improve the treatment of cancer-related catechexia, the reduced intake, and utilization of food (Prof. Dr. Osama Sabri). The Department of Otolaryngology at UKL (Prof. Dr. Andreas Dietz) is researching the personalized treatment of esophageal cancer.
The scientists are collaborating with researchers from Denmark, France, Greece, Italy, Norway, and Spain.
Chimeric Antigen Receptor T Cell Therapy (CAR-T): Genetically programmed immune cell binds to and destroys cancer cell / Therapy is now available for the majority of indications
The Smart Infrastructure Hub Leipzig will receive a further 1,9 million euros from the cluster funding of the Saxon Ministry of Economic Affairs.
A relatively small metropolis in Germany’s Free State of Saxony – a dynamic hub for the life science industry? What was just a vision 20 years ago has become a reality for the city of Leipzig, which from October 24-26 co-hosted BIO-Europe, Europe’s largest annual biotech partnering event.
The European Commission has approved the Saxon ERDF/JTF program for the funding period 2021 to 2027.